Eyenuk

Executive Summary

Eyenuk is a Los Angeles-based private company founded in 1996 that harnesses deep learning to prevent blindness. Its core technology, EyeArt, is an FDA-cleared autonomous AI system for detecting diabetic retinopathy (DR) from retinal images. In June 2023, Eyenuk became the first company to receive FDA clearance for multiple camera types, expanding the accessibility of its AI-powered DR screening. With over 400 million people worldwide at risk for diabetic retinopathy, Eyenuk’s cost-effective, point-of-care solution addresses a significant unmet need in chronic disease management. The company is positioned to scale through partnerships with telemedicine platforms, primary care clinics, and eye care providers, aiming to reduce preventable blindness globally. While Eyenuk is established in its regulatory pathway, its commercial traction and revenue remain undisclosed, representing both an opportunity and risk for stakeholders.

Upcoming Catalysts (preview)

• Q4 2026Expansion of FDA clearance to additional camera models or indications (e.g., glaucoma detection)80% success
• Q1 2027New strategic partnership with a major healthcare system or payer for nationwide deployment65% success
• Q2 2027Publication of real-world evidence from large-scale screening programs demonstrating clinical utility75% success